Sanofi and Denali Therapeutics Collaborates to Develop & Commercialize Clinical Candidates for Neurology and Inflammatory Disorders

 Sanofi and Denali Therapeutics Collaborates to Develop & Commercialize Clinical Candidates for Neurology and Inflammatory Disorders

Sanofi and Denali Therapeutics Collaborates to Develop & Commercialize Clinical Candidates for Neurology and Inflammatory Disorders

 Shots:

  • Denali to get $125M upfront plus milestones payments that can exceed $1B and will also receive royalties for DNL747 (ex-US & China) & DNL758 (WW). The profit/loss sharing will be divided equally and this partnership also includes pre-clinical RIPK1 inhibitor candidate
  • Sanofi will fund DNL747 (P-Ib & P-II) & DNL747 in MS (multiple sclerosis), ALS (amyotrophic lateral sclerosis) & systemic inflammatory diseases respectively. Alzheimer’s disease will be funded by Denali for DNL747. For neurology disorders Sanofi (70%) & Denali (30%) will jointly fund P-III trial
  • DNL747 & DNL758 are being developed for targeting RIPK1 protein. DNL747 is currently evaluated in P-I while P-II will be expected to initiate in 2019

Click here to read full press release/ article | Ref: Sanofi | Image: Chemistry World

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post